Intech Investment Management LLC Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Intech Investment Management LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,898 shares of the biopharmaceutical company’s stock after selling 5,695 shares during the quarter. Intech Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Marcum Wealth LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $201,000. Bruce G. Allen Investments LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $40,000. Dynamic Advisor Solutions LLC increased its stake in shares of Regeneron Pharmaceuticals by 13.3% in the fourth quarter. Dynamic Advisor Solutions LLC now owns 877 shares of the biopharmaceutical company’s stock worth $801,000 after purchasing an additional 103 shares in the last quarter. Raymond James Trust N.A. increased its stake in shares of Regeneron Pharmaceuticals by 11.0% in the fourth quarter. Raymond James Trust N.A. now owns 958 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 95 shares in the last quarter. Finally, Whittier Trust Co. lifted its stake in shares of Regeneron Pharmaceuticals by 168.8% during the 4th quarter. Whittier Trust Co. now owns 774 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 486 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the sale, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the sale, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,074 shares of company stock valued at $64,546,123. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. Argus lifted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Bank of America lifted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Piper Sandler increased their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an “overweight” rating in a report on Friday. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $1,063.82.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $3.66 during trading on Friday, hitting $1,063.60. 452,210 shares of the stock traded hands, compared to its average volume of 453,015. The stock has a market cap of $117.20 billion, a price-to-earnings ratio of 31.42, a PEG ratio of 2.20 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $720.00 and a 52 week high of $1,106.16. The firm’s fifty day moving average is $1,025.07 and its 200-day moving average is $971.85.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.